Is Nutex Health, Inc. overvalued or undervalued?

As of 7 July 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive, indicating a strong positive shift in its perceived value. The company appears to be undervalued based on its key ratios, including a P/E ratio of 5, an EV to EBITDA ratio of 2.82, and an impressive ROCE of 128.63%.
When compared to peers, Nutex Health's valuation metrics stand out; for example, Fulgent Genetics, Inc. has a P/E ratio of -21.28, and Talkspace, Inc. is considered expensive with a P/E of 156.07. Despite some recent volatility, Nutex Health has significantly outperformed the S&P 500 over the year, with a return of 273.93% compared to the S&P 500's 17.14%, reinforcing its attractive valuation story.